Initially elevated osteoprotegerin serum levels may predict a perioperative myocardial lesion in patients undergoing coronary artery bypass grafting

Critical Care Medicine

Volumn 34, Issue 1, 2006, Pages 76-80

  Hermann Arnhof, K M ^a   Kastenbauer T ^a   Publig, T ^a   Novotny, P ^b   Loho, N ^b   Schwarz, S ^b   Koller U ^a   Fitzgerald, R ^b  

^a GENERAL HOSPITAL LINZ   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Cardiac troponin I; Coronary artery bypass grafting; Coronary artery disease; Electrocardiography; Homocysteine; Osteoprotegerin

Indexed keywords

HOMOCYSTEINE; OSTEOPROTEGERIN;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORRELATION ANALYSIS; ELECTIVE SURGERY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN DETERMINATION; SURGICAL PATIENT;

EID: 29744442088     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000190429.52746.33     Document Type: Article

References (32)

1. Vattikuti R, Towler DA: Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab 2004; 286:E686-E696
2. Varghese K, Cherian G, Abraham UT, et al: Predictors of coronary disease in patients with end stage renal disease. Ren Fail 2001; 23:797-806
3. Collin-Osdoby P: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 95:1046-1057
4. Tintut Y, Demer LL: Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol 2001; 12:555-560
5. Rifai N, Ridker PM: High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease. Clin Chem 2001; 47:403-411
6. Whitney C, Warburton DE, Frohlich J, et al: Are cardiovascular disease and osteoporosis directly linked? Sports Med 2004; 34:779-807
7. Ueland T, Jemtland R, Godang K, et al: Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004; 44:1970-1976
8. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292:490-495
9. Sattler AM, Schoppet M, Schaefer JR, et al: Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004; 74:103-106
10. Rhee EJ, Lee WY, Kim SY, et al: The relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond) 2005; 108:237-243
11. Ritchlin CT, Schwarz EM, O'Keefe RJ, et al: RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. J Musculoskelet Neuronal Interact 2004; 4:276-284
12. Franchimont N, Reenaers C, Lambert C, et al: Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004; 138:491-498
13. Saidenberg-Kermanac'h N, Corrado A, Lemeiter D, et al: TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 2004; 35:1200-1207
14. Nageh T, Sherwood RA, Harris BM, et al: Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention. Int J Cardiol 2003; 92:285-293
15. Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319
16. Yun TJ, Chaudhary PM, Shu GL, et al: OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is upregulated by ligating CD40. J Immunol 1998; 161:6113-6121
17. Bucay N, Sarosi I, Dunstan CR, et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-1268
18. Min H, Morony S, Sarosi I, et al: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192:463-474
19. Dhore CR, Cleutjens JP, Lutgens E, et al: Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21:1998-2003
20. Browner WS, Lui LY, Cummings SR: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86:631-637
21. Jono S, Ikari Y, Shioi A, et al: Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106:1192-1194
22. Schoppet M, Sattler AM, Schaefer JR, et al: Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003; 88:1024-1028
23. Soufi M, Schoppet M, Sattler AM, et al: Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 2004; 89:3764-3768
24. Bodi V, Sanchis J, Llacer A, et al: Risk stratification in non-ST elevation acute coronary syndromes: Predictive power of troponin I, C-reactive protein, fibrinogen and homocysteine. Int J Cardiol 2005; 98:277-283
25. Oh ES, Rhee EJ, Oh KW, et al: Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism 2005; 54:49-54
26. Gannage-Yared MH, Azoury M, Mansour I, et al: Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest 2003; 26:748-753
27. Solomon DH, Curhan GC, Rimm EB, et al: Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004; 50:3444-3449
28. Noora J, Ricci C, Hastings D, et al: Determination of troponin I release after CABG surgery. J Card Surg 2005; 20:129-135
29. Fahrleitner A, Prenner G, Kniepeiss D, et al: Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. Wien Klin Wochenschr 2002; 114:717-724
30. Malyszko J, Malyszko JS, Wolczynski S, et al: Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. Transplant Proc 2003; 35:2227-2229
31. Hofbauer LC, Shui C, Riggs BL, et al: Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 2001; 280:334-339
32. Di Munno O, Mazzantini M, Delle Sedie A, et al: Risk factors for osteoporosis in female patients with systemic lupus erythematosus. Lupus 2004; 13:724-730